OBJECTIVE: The unfolded protein response (UPR) is a conserved cellular response designed to alleviate damage and promote survival of cells experiencing stress; however, prolonged UPR activation can result in apoptotic cell death. The UPR, activated by cytokine-induced nitric oxide (NO) production, has been proposed to mediate beta-cell death in response to cytokines. In this study, the role of UPR activation in cytokine-induced beta-cell death was examined. RESEARCH DESIGN AND METHODS: The effects of cytokine treatment of rat and human islets and RINm5F cells on UPR activation, NO production, and cell viability were examined using molecular and biochemical methodologies. RESULTS: UPR activation correlates with beta-cell death in interleukin (IL)-1-treated rat islets. NO mediates both cytokine-induced UPR activation and beta-cell death as NO synthase inhibitors attenuate each of these IL-1-stimulated events. Importantly, cytokines and tunicamycin, a classical UPR activator, induce beta-cell death by different mechanisms. Cell death in response to the classical UPR activator is associated with a 2.5-fold increase in caspase-3 activity, while IL-1 fails to stimulate caspase-3 activity. In addition, cell death is enhanced by approximately 35% in tunicamycin-treated cells expressing an S51A eIF2 alpha mutant that cannot be phosphorylated or in cells lacking PERK (protein kinase regulated by RNA/endoplasmic reticulum-like kinase). In contrast, neither the absence of PERK nor the expression of the S51A eIF2 alpha mutant affects the levels of cytokine-induced death. CONCLUSIONS: While cytokine-induced beta-cell death temporally correlates with UPR activation, the lack of caspase activity and the ability of NO to attenuate caspase activity suggest that prolonged UPR activation does not mediate cytokine-induced beta-cell death.
OBJECTIVE: The unfolded protein response (UPR) is a conserved cellular response designed to alleviate damage and promote survival of cells experiencing stress; however, prolonged UPR activation can result in apoptotic cell death. The UPR, activated by cytokine-induced nitric oxide (NO) production, has been proposed to mediate beta-cell death in response to cytokines. In this study, the role of UPR activation in cytokine-induced beta-cell death was examined. RESEARCH DESIGN AND METHODS: The effects of cytokine treatment of rat and human islets and RINm5F cells on UPR activation, NO production, and cell viability were examined using molecular and biochemical methodologies. RESULTS: UPR activation correlates with beta-cell death in interleukin (IL)-1-treated rat islets. NO mediates both cytokine-induced UPR activation and beta-cell death as NO synthase inhibitors attenuate each of these IL-1-stimulated events. Importantly, cytokines and tunicamycin, a classical UPR activator, induce beta-cell death by different mechanisms. Cell death in response to the classical UPR activator is associated with a 2.5-fold increase in caspase-3 activity, while IL-1 fails to stimulate caspase-3 activity. In addition, cell death is enhanced by approximately 35% in tunicamycin-treated cells expressing an S51AeIF2 alpha mutant that cannot be phosphorylated or in cells lacking PERK (protein kinase regulated by RNA/endoplasmic reticulum-like kinase). In contrast, neither the absence of PERK nor the expression of the S51AeIF2 alpha mutant affects the levels of cytokine-induced death. CONCLUSIONS: While cytokine-induced beta-cell death temporally correlates with UPR activation, the lack of caspase activity and the ability of NO to attenuate caspase activity suggest that prolonged UPR activation does not mediate cytokine-induced beta-cell death.
Authors: Bernhard Maier; Takeshi Ogihara; Anthony P Trace; Sarah A Tersey; Reiesha D Robbins; Swarup K Chakrabarti; Craig S Nunemaker; Natalie D Stull; Catherine A Taylor; John E Thompson; Richard S Dondero; Eli C Lewis; Charles A Dinarello; Jerry L Nadler; Raghavendra G Mirmira Journal: J Clin Invest Date: 2010-05-24 Impact factor: 14.808
Authors: Bryndon J Oleson; Katarzyna A Broniowska; Chay Teng Yeo; Michael Flancher; Aaron Naatz; Neil Hogg; Vera L Tarakanova; John A Corbett Journal: Mol Cell Biol Date: 2019-08-27 Impact factor: 4.272
Authors: F Allagnat; F Christulia; F Ortis; P Pirot; S Lortz; S Lenzen; D L Eizirik; A K Cardozo Journal: Diabetologia Date: 2010-03-29 Impact factor: 10.122
Authors: Sarah A Tersey; Bernhard Maier; Yurika Nishiki; Aarthi V Maganti; Jerry L Nadler; Raghavendra G Mirmira Journal: Mol Cell Biol Date: 2014-07-28 Impact factor: 4.272
Authors: Gordon P Meares; Dominique Fontanilla; Katarzyna A Broniowska; Teresa Andreone; Jack R Lancaster; John A Corbett Journal: Am J Physiol Endocrinol Metab Date: 2013-01-15 Impact factor: 4.310
Authors: Katarzyna A Broniowska; Bryndon J Oleson; Jennifer McGraw; Aaron Naatz; Clayton E Mathews; John A Corbett Journal: J Biol Chem Date: 2015-02-03 Impact factor: 5.157